While early mutations in chromatin modifiers like IDH1/2 are pivotal in glioma development, their roles may evolve from driving to secondary as the cancer progresses, challenging the effectiveness of targeting these mutations [36]. The gene discussed is IDH1; the disease is central nervous system cancer.